Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: A retrospective analysis

Infection

Volumn 40, Issue 2, 2012, Pages 153-161

  Roll, D ^a   Ammer, J ^a   Holler, B ^a   Salzberger, B ^a   Schweiger, B ^b   Jilg, W ^a   Andreesen, R ^a   Edinger, M ^a   Wolff, D ^a   Holler, E ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

GvHD; Hematopoietic stem cell transplantation; Influenza; Rituximab; Vaccination

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; PREDNISONE; STEROID;

2009 H1N1 INFLUENZA; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFLUENZA VACCINATION; MALE; MEMORY CELL; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; REMISSION; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; VACCINE FAILURE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, HUMORAL; IMMUNOSUPPRESSION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; TRANSPLANTATION, HOMOLOGOUS; VACCINATION; YOUNG ADULT;

EID: 84863206888     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-011-0206-5     Document Type: Article

References (33)

1. Michaelis M, Doerr HW, Cinatl J Jr. An influenza A H1N1 virus revival-pandemic H1N1/09 virus. Infection. 2009;37:381-9.
2. Reinheimer C, Allwinn R, Doerr HW. Limited prevalence of influenza A/H1N1v antibodies: footprints of the pandemic of 2010. Infection. 2011;39:101-4.
3. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-15.
4. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361:680-9.
5. Harris KM, Maurer J, Kellermann AL. Influenza vaccine-safe, effective, and mistrusted. N Engl J Med. 2010;363:2183-5.
6. Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis. 2010;16:1068-75.
7. Wei JY, Chen FF, Jin J, et al. Novel influenza A (H1N1) in patients with hematologic disease. Leuk Lymphoma. 2010;51:2079-83.
8. Seiter K, Nadelman RB, Liu D, et al. Novel Influenza A (H1N1) in patients with hematologic malignancies. J Clin Oncol. 2010;28:27-9.
9. Espinosa-Aguilar L, Green JS, Forrest GN, et al. Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers experiences. Biol Blood Marrow Transpl. 2011;17:566-73.
10. Choi SM, Boudreault AA, Xie H (2011) Differences in clinical outcomes following 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 117:5050-6.
11. Hilgendorf I, Jilg W, Einsele H, et al. Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the International Consensus Conference on Clinical Practice in chronic GVHD. Vaccine. 2011;29:2825-33.
12. Garland P, de Lavallade H, Sekine T, et al. Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transpl. 2011;17:632-9.
13. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transpl. 2011;17:434-8.
14. Redelman-Sidi G, Sepkowitz KA, Huang CK, et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect. 2010;60:257-63.
15. Engelhard D, Zakay-Rones Z, Shapira MY, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1) v-like virus vaccine during the 2009 pandemic. Vaccine. 2011;29: 1777-82.
16. Filipovich AH. Diagnosis and manifestations of chronic graftversus-host disease. Best Pract Res Clin Haematol. 2008;21: 251-7. (Pubitemid 351712714)
17. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825-8.
18. Mitchell SA, Kline Leidy N, Mooney KH, et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versushost disease (cGVHD). Bone Marrow Transpl. 2009;45:762-9.
19. Allwinn R, Geiler J, Berger A, et al. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is prevalence rate of protecting antibodies in humans? Med Microbiol Immunol. 2010;199:117-21.
20. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405-13.
21. Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010;375:41-8.
22. Mackay HJ, McGee J. Villa D: evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol. 2011;50:212-6.
23. Lu CC, Wang YC, Lai JH, et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus. Safety ImmunVaccine. 2011;29:444-50.
24. Pollyea DA, Brown JMY, Horning S. Utility of influenza vaccination for oncology patients. J Clin Oncol. 2010;28:2481-90.
25. Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk Lymphoma. 1999;32:369-74. (Pubitemid 29087820)
26. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. British J Haematol. 2005;130:96-8. (Pubitemid 40979139)
27. Gueller S, Allwinn R, Mousset S, et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1546-50.
28. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Guidelines. Bone Marrow Transpl. 2009;44:521-6.
29. Takata T, Suzumiya J, Ishikawa T, et al. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-Cell lymphoma after the administration of Rituximab-CHOP. J Clin Exp Hematopathol. 2009;49:9-13.
30. Pollyea DA, Brown JMY, Horning S. Utility of influenza vaccination for oncology patients. J Clin Oncol. 2010;28:2481-90.
31. van Assen S, Holvast A, Benne CA. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthr Rheum. 2010; 62:75-81.
32. Frasca D, Diaz A, Romero M, et al. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine. 2010;28:8077-84.
33. Greinix HT, Pohlreich D, Kouba M. Elevated numbers of immature/transitional CD21-B lymphocytes and deficiency of memory CD27? B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2008;14: 208-19.